Trial Profile
Phase I study of soblidotin and gemcitabine in patients with locally advanced or metastatic solid tumors
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 12 Jul 2013
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Soblidotin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 29 Sep 2006 Status change
- 24 Sep 2005 New trial record.